These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 27922482)

  • 1. Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1: Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry Biomarkers.
    Cheung CC; D'Arrigo C; Dietel M; Francis GD; Gilks CB; Hall JA; Hornick JL; Ibrahim M; Marchetti A; Miller K; van Krieken JH; Nielsen S; Swanson PE; Taylor CR; Vyberg M; Zhou X; Torlakovic EE;
    Appl Immunohistochem Mol Morphol; 2017 Jan; 25(1):4-11. PubMed ID: 27922482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance Characteristics.
    Torlakovic EE; Cheung CC; D'Arrigo C; Dietel M; Francis GD; Gilks CB; Hall JA; Hornick JL; Ibrahim M; Marchetti A; Miller K; van Krieken JH; Nielsen S; Swanson PE; Vyberg M; Zhou X; Taylor CR;
    Appl Immunohistochem Mol Morphol; 2017 Feb; 25(2):79-85. PubMed ID: 28182587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC Laboratories.
    Torlakovic EE; Cheung CC; D'Arrigo C; Dietel M; Francis GD; Gilks CB; Hall JA; Hornick JL; Ibrahim M; Marchetti A; Miller K; van Krieken JH; Nielsen S; Swanson PE; Vyberg M; Zhou X; Taylor CR;
    Appl Immunohistochem Mol Morphol; 2017 Mar; 25(3):151-159. PubMed ID: 28187030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 4: Tissue Tools for Quality Assurance in Immunohistochemistry.
    Cheung CC; D'Arrigo C; Dietel M; Francis GD; Fulton R; Gilks CB; Hall JA; Hornick JL; Ibrahim M; Marchetti A; Miller K; van Krieken JH; Nielsen S; Swanson PE; Taylor CR; Vyberg M; Zhou X; Torlakovic EE;
    Appl Immunohistochem Mol Morphol; 2017 Apr; 25(4):227-230. PubMed ID: 27941560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fit-for-Purpose Immunohistochemical Biomarkers.
    Torlakovic EE
    Endocr Pathol; 2018 Jun; 29(2):199-205. PubMed ID: 29696583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Institutional quality assurance for breast cancer HER2 immunohistochemical testing: identification of outlier results and impact of simultaneous fluorescence in situ hybridization cotesting.
    Green IF; Zynger DL
    Hum Pathol; 2015 Dec; 46(12):1842-9. PubMed ID: 26412217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated UK Recommendations for HER2 assessment in breast cancer.
    Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
    J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoplex LightCycler polymerase chain reaction quantitation of the HER2 gene for quality assurance of HER2/neu testing by immunohistochemistry and fluorescence in situ hybridization.
    Layfield LJ; Willmore-Payne C; Isom G; Holden JA
    Appl Immunohistochem Mol Morphol; 2008 Dec; 16(6):562-7. PubMed ID: 18948825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Digitalization and multiplex IHC as predictive biomarkers for novel immune-therapeutics : New challenges for immunohistochemistry].
    Zielinski D
    Pathologe; 2019 May; 40(3):256-263. PubMed ID: 31089796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
    Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 testing guidelines: a 3-year comparison of validation procedures.
    Dyhdalo KS; Fitzgibbons PL; Goldsmith JD; Souers RJ; Nakhleh RE
    Arch Pathol Lab Med; 2014 Jul; 138(7):876-84. PubMed ID: 24978913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemistry-Enabled Precision Medicine.
    Gatalica Z; Feldman R; Vranić S; Spetzler D
    Cancer Treat Res; 2019; 178():111-135. PubMed ID: 31209843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving Selection Criteria for ALK Inhibitor Therapy in Non-Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry.
    Jiang L; Yang H; He P; Liang W; Zhang J; Li J; Liu Y; He J
    Am J Surg Pathol; 2016 May; 40(5):697-703. PubMed ID: 26825369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
    Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
    Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
    Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study.
    Hanna WM; Barnes PJ; Chang MC; Gilks CB; Magliocco AM; Rees H; Quenneville L; Robertson SJ; SenGupta SK; Nofech-Mozes S
    J Clin Oncol; 2014 Dec; 32(35):3967-73. PubMed ID: 25385731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria.
    von Laffert M; Warth A; Penzel R; Schirmacher P; Kerr KM; Elmberger G; Schildhaus HU; Büttner R; Lopez-Rios F; Reu S; Kirchner T; Pauwels P; Specht K; Drecoll E; Höfler H; Aust D; Baretton G; Bubendorf L; Stallmann S; Fisseler-Eckhoff A; Soltermann A; Tischler V; Moch H; Penault-Llorca F; Hager H; Schäper F; Lenze D; Hummel M; Dietel M
    J Thorac Oncol; 2014 Nov; 9(11):1685-92. PubMed ID: 25436802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
    Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK
    Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers and biomarker validation: a pathologist's guide to getting it right.
    Paver EC; Morey AL
    Pathology; 2024 Mar; 56(2):147-157. PubMed ID: 38195376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.